Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible (Global Initiative for Chronic Obstructive Lung Disease 2006). Even with the best available care, lung function in patients with COPD progressively worsens over time. Maintaining or improving health-related quality of life (HRQoL) is, therefore, a key treatment goal in COPD and should be one of the main parameters for monitoring the disease and assessing the efficacy of treatment.

Clinical trials have widely employed health status questionnaires as markers of the impact of disease on patients' health, daily life, and sense of well-being ([@b25-copd-3-301], [@b24-copd-3-301]; [@b12-copd-3-301]). Many HRQoL questionnaires exist, including disease-specific instruments such as the St. George's Respiratory Questionnaire (SGRQ) ([@b13-copd-3-301]) and generic instruments such as the 36-item short form (SF-36) ([@b17-copd-3-301]). These questionnaires have been used in patients with stable COPD and during exacerbations ([@b24-copd-3-301]), as well as in the evaluation of new therapies ([@b25-copd-3-301]; [@b12-copd-3-301]). In particular, the SGRQ has been validated in many languages, including French ([@b2-copd-3-301]).

Despite the existence of numerous HRQoL questionnaires, none has been specifically designed and validated for use in the treatment of COPD in routine medical practice. Indeed, PW Jones recently highlighted the issue that tools used to assess HRQoL in clinical trials by pharmaceutical companies and/or payers should be differentiated from those designed to detect an improvement in HRQoL in an individual patient ([@b14-copd-3-301]). HRQoL is not easy to measure in routine medical practice. The lack of a convenient tool in French instigated the development of the disease-specific Visual Simplified Respiratory Questionnaire (VSRQ) by Boehringer Ingelheim, France. The focus of this paper is on the efficacy of tiotropium compared with placebo on HRQoL as measured by the SGRQ. The VSRQ questionnaire has been included in this study to undergo a preliminary evaluation, but the data on the validation of this new instrument will not be the subject of the current paper and will be published elsewhere.

Tiotropium (Spiriva^®^; Boehringer Ingelheim GmbH; Ingelheim am Rhein, Germany) is a once-daily anticholinergic that provides effective 24-hour efficacy through prolonged M~3~-receptor blockade and is indicated for maintenance treatment of patients with COPD. Previous studies have consistently shown that tiotropium significantly improves lung function, favorably influences exercise capacity, reduces dyspnea and also the incidence of exacerbations in patients with COPD ([@b4-copd-3-301]; [@b29-copd-3-301]; [@b3-copd-3-301]; [@b5-copd-3-301]; [@b19-copd-3-301]; [@b18-copd-3-301]; [@b28-copd-3-301]; [@b10-copd-3-301]). It has also been shown to improve HRQoL compared with placebo ([@b4-copd-3-301]; [@b9-copd-3-301]; [@b29-copd-3-301]; [@b28-copd-3-301]). Furthermore, tiotropium has been shown to be superior to placebo in terms of the proportion of patients achieving a reduction of at least 4 units in the SGRQ total score ([@b9-copd-3-301]). However, these studies monitored HRQoL only as a secondary efficacy parameter.

The primary aim of the present study was to investigate the effects of 9 months' treatment with tiotropium 18 μg on HRQoL in patients with moderate-to-severe COPD, using the SGRQ. The assessment of HRQoL as a primary endpoint has, to our knowledge, not been previously evaluated in any other clinical trials of pharmacologic interventions in COPD.

Materials and methods
=====================

Patients
--------

Male and female outpatients aged ≥40 years with a clinical diagnosis of COPD (pre- and post-bronchodilator FEV~1~ 20%--70% predicted and FEV~1~/slow vital capacity \[SVC\] ≤70%,) corresponding to mild, moderate, or severe COPD according to 1995 American Thoracic Society criteria ([@b1-copd-3-301]) and a smoking history of \>10 pack-years were eligible for inclusion in the study. Exclusion criteria were a history of asthma, allergic rhinitis, or atopy; regular use of daytime oxygen therapy; a recent respiratory tract infection (within the previous 6 weeks); a recent history of myocardial infarction (within the previous 6 months); cardiac arrhythmia requiring drug therapy (within the previous year); or hospitalization for either heart failure or pulmonary edema (within the previous 3 years).

Study design
------------

This was a 9-month, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. The trial (protocol 205.256) was performed at 123 centers in France. Patients were recruited between May 2002 and June 2003, and follow up was from August 2002 through April 2004. The trial was approved by an ethics committee (Comité Consultatif de Protection des Personnes dans la Recherche Biomedicale \[CCPPRB\] of Lille), conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent.

Following a screening visit (Day -- 14), eligible patients underwent a 2-week run-in period during which any short-acting anticholinergics or long-acting β~2~-agonists were washed out. On Day 1 of the study, patients were randomized 1:1 to receive either tiotropium 18 μg once daily or placebo, delivered via the HandiHaler^®^ device (Boehringer Ingelheim GmbH; Germany). Patients were assigned using a computer-generated randomization schedule, with no stratification (block size of 4).

Patients were permitted to use salbutamol (Ventolin^®^; GlaxoSmithKline, UK) delivered via a metered-dose inhaler, as needed, for acute symptom relief. Concomitant use of theophylline preparations (excluding 24-hour preparations), mucolytics, inhaled corticosteroids (ICS), and oral steroids (at a dose of \<10 mg prednisone daily or equivalent) was allowed if the dosage was stabilized for ≥6 weeks before study entry. During the treatment period, patients were not allowed to use β-blockers, antileukotrienes, oral or inhaled long-acting β~2~-agonists, short-acting anticholinergics, or any other investigational drug. One 10-day course of oral steroids was permitted for the treatment of a COPD exacerbation during the study period. Investigators were also permitted to administer antibiotics as deemed necessary for the treatment of exacerbations.

Clinical assessments
--------------------

Assessments were conducted prior to administration of treatment on Day 1 (randomization) and after 3, 6, and 9 months of treatment. The primary efficacy endpoint was the proportion of patients achieving a reduction of at least 4 units in the SGRQ total score at study end (Month 9). In order to avoid the introduction of a bias in the completion of the HRQoL questionnaires, these were completed prior to the spirometric tests using the SGRQ and the VSRQ on each test day. The SGRQ consists of a 76-item questionnaire split into 3 components: symptoms (assessing distress due to respiratory symptoms), activity (assessing the effects of breathlessness on mobility and physical activity), and impact (assessing the psychosocial impact of disease). The SGRQ total score is a composite of the 3 component scores. Scores are weighted and range from 0 to 100, with higher scores indicating a poorer HRQoL. Currently, a *reduction* of ≥4 units is considered to be the minimal clinically important difference by the author of the questionnaire ([@b15-copd-3-301]), but this value is currently under debate and subject to review. Subgroup analyses were performed according to COPD severity, reversibility at baseline, ICS use and occurrence of exacerbations during the trial.

The VSRQ consists of 8 items (dyspnea, usual daily activities, social activities, quality of sleep, pleasure, energy, anxiety, and sexual life) that are each rated from 0 (extreme limitation) to 10 (no limitation) on a visual scale. The VSRQ total score is the sum of these 8 ratings. An increase indicates an improvement in health status. More details about the questionnaire and the validation data from this trial will be published elsewhere.

FEV~1~, forced vital capacity (FVC), inspiratory capacity (IC), SVC, and forced inspiratory volume in 1 second (FIV~1~; measured at selected sites only) were recorded 30 minutes prior to dosing on Day 1 and approximately 24 hours after the previous dose of study medication at 3, 6, and 9 months. All spirometric tests were conducted in triplicate, and the highest measurements were used in subsequent analyses.

Detailed information on exacerbations of COPD was also collected. An acute exacerbation was defined as a sustained worsening of the patient's COPD (from the stable state and beyond normal day-to-day variation) that was acute in onset and necessitated a change in regular medication ([@b22-copd-3-301]). Adverse events were monitored throughout the treatment period and coded according to the Medical Dictionary for Drug Regulatory Affairs, MedDRA version 7.0.

Statistical analysis
--------------------

A sample size of 234 patients per treatment group was required to provide 80% power to detect a between-group difference of 13% in the primary endpoint (proportion of patients with ≥4 units improvement in SGRQ total score). This difference corresponds to expected response rates of 32% and 45% in the placebo and tiotropium groups, respectively (2-sided χ^2^ test at a 5% confidence level). The sample size calculation based on a 13% difference was determined considering the findings of the pooled results from two 6-month trials ([@b3-copd-3-301]) comparing tiotropium, salmeterol and placebo. The difference between tiotropium and placebo after 6 months was 10%. The other data taken into consideration was the pooled analysis of two 1-year placebo-controlled tiotropium trials ([@b4-copd-3-301]), showing a difference of 19% after 12 months.

Due to the fact that this trial had a duration that is in between that of the two reference trials and, under the assumption that the HRQoL will deteriorate over time, the assumption of a 13% difference was taken. Another assumption was that the pattern of concomitant medication use has changed over time and that there is a higher likelihood of concomitant respiratory medication use in this trial, as compared with the earlier trials used as reference.

Efficacy was measured in the full analysis population, which included all randomized patients who received study medication and had baseline and at least 1 valid post-treatment measurement. This included patients who dropped out prematurely, but these patients were not followed up until the projected exit date from the trial. Patients who did not adhere to the protocol or who were treated for less than 30 days were excluded from the per-protocol analyses. The safety population included all randomized patients who received study medication. Missing individual SGRQ items were handled according to the questionnaire authors' recommendations: missing items from Part 1 or Part 2 (sections 1 and 7 \[last part\]) of the questionnaire were imputed as negative responses. If individual SGRQ items were missing from Part 2 (sections 2--6 and 7 \[first part\] of the questionnaire), the total weight was adjusted to take into account the missing values. If more than 10 items were missing in these sections, then the component score was not included in the subsequent analyses. The maximum numbers of missing items were 2, 4, and 6 for the symptoms, activity, and impacts components, respectively. Moreover, missing SGRQ component or total scores were imputed using the last observation carried forward method (except if Day 1 was the last visit, in which case the patient was excluded). The VSRQ total score was calculated from the 8 category scores. As there was no specific recommendation for handling missing data, the last observation carried forward method was used.

The primary endpoint was analyzed using the Cochran-Mantel-Haenszel test, stratified by center. Analysis of covariance with terms for treatment was used for all the HRQoL and spirometric endpoints, with baseline data as covariates. Four subgroups were defined: FEV~1~ severity (below and above 50% predicted value) and reversibility at baseline, use of concomitant inhaled corticosteroids (yes/no), and occurrence of exacerbations (yes/no) during the trial. The subgroup analysis of changes from baseline in SGRQ total scores was performed using an analysis of covariance model with the factors treatment, subgroup, and subgroup-by-treatment interaction with the baseline values as covariate.

The Fisher exact test was used to compare the frequency of exacerbations. The Wilcoxon-Mann-Whitney test was used to compare the number of exacerbations days. Exacerbation endpoints were calculated per patient per year by dividing the number of events by the treatment exposure and multiplying by 365.25. Pairwise treatment comparisons of time to the first COPD exacerbation from Kaplan-Meier estimates were made using the log rank test.

Results
=======

Patients
--------

A total of 555 patients were randomized and 554 received treatment, with 266 receiving tiotropium and 288 receiving placebo ([Figure 1](#f1-copd-3-301){ref-type="fig"}). Patients who dropped out but had baseline and post-treatment data were included in the full analysis dataset, following the intent-to-treat principle. 492 patients (tiotropium, n = 247; placebo, n = 245) had sufficient data for inclusion in the full analysis population for the SGRQ total score analysis. More patients in the placebo group discontinued the trial than in the tiotropium group (25.7% vs 14.7%, p = 0.0013) ([Figure 1](#f1-copd-3-301){ref-type="fig"}). In general, the 2 treatment groups were well matched at baseline ([Table 1](#t1-copd-3-301){ref-type="table"}). However, while the mean ± SD baseline SGRQ total score for all patients was 47.4 ± 18.1, the mean SGRQ total score was significantly higher in the placebo group than the tiotropium group (difference, 3.2; p = 0.046) ([Table 1](#t1-copd-3-301){ref-type="table"}). Furthermore, the mean baseline SGRQ total score was significantly higher in the subgroup of patients with more severe disease (FEV~1~ ≤ 50% predicted) than in patients with milder disease (FEV~1~ \> 50% predicted) (49.7 vs 43.5, respectively).

HRQoL
-----

Compared with the placebo group, significantly more patients in the tiotropium group achieved a reduction of at least 4 units in the SGRQ total score at Month 9 ([Figure 2](#f2-copd-3-301){ref-type="fig"}). At study end, 59.1% (146/247) patients in the tiotropium group had exceeded this threshold that is, despite ongoing discussions, currently regarded as a clinically meaningful improvement in SGRQ total score. These patients were considered as responders, compared with 48.2% (118/245) of patients in the placebo group (difference 10.9% \[95% confidence interval (CI), 2.19% to 19.71%\]; p = 0.029).

Tiotropium significantly improved the SGRQ total score on each test day, compared with placebo (all p \< 0.05) ([Figure 3a](#f3-copd-3-301){ref-type="fig"}). At study end, adjusted mean (SE) change from baseline SGRQ total scores was −8.50 (0.90) for tiotropium and −4.32 (0.90) for placebo. The difference between the 2 groups exceeded the change of at least 4 units in the SGRQ total score currently regarded as meaningful (difference, −4.19 \[95% CI, −6.68 to −1.69\]; p = 0.001). Furthermore, compared with placebo, tiotropium significantly improved all 3 SGRQ domain scores at study end (all p \< 0.05) ([Figure 3b](#f3-copd-3-301){ref-type="fig"}).

When the overall study population is divided into subgroups according to baseline criteria (disease severity and reversibility), and on concomitant ICS use and exacerbations during the trial, tiotropium showed a consistent efficacy pattern across the subgroups. The interaction analysis of treatment by subgroup did not reveal any significant interactions ([Table 2](#t2-copd-3-301){ref-type="table"}).

When we compared changes in SGRQ scores in 2 sub-groups according to FEV~1~ values (higher or lower than 50% predicted), SGRQ total score improvement was statistically significantly better in more severe patients. The difference between the tiotropium and the placebo group was, despite the consistent effect of tiotropium, small and did not reach statistical significance in less severe patients. In patients receiving ICS, the difference in SGRQ between tiotropium and placebo did not reach statistical significance, most likely due to the low sample size that was not powered to detect a difference. When the change in the HRQoL is analyzed by the occurrence of exacerbations, patients in the placebo group do show a clear relationship between lesser improvement in HRQoL and the occurrence of at least one exacerbation. This difference is less pronounced in the patients on tiotropium treatment ([Table 2](#t2-copd-3-301){ref-type="table"}).

Spirometry
----------

At study end, tiotropium improved predose FEV~1~, FIV~1~, FVC, IC, and SVC compared with placebo (all p \< 0.05) ([Figure 4](#f4-copd-3-301){ref-type="fig"}). (FIV~1~ was analyzed in 80.5% of the full analysis population.) There was no significant correlation between improvements in the SGRQ total score in both groups and changes in FEV~1~ (r = −0.18), FIV~1~ (r = −0.14), FVC (r = −0.15), IC (r = −0.07), or SVC (r = −0.17) at study end. However, when we compared changes from baseline in SGRQ scores in 2 subgroups according to FEV~1~ values (higher or lower than 50 % pred), SGRQ total score improvement was statistically significantly better in the more severe patients, in favor of the tiotropium group. In those with FEV~1~ ≤ 50% pred, the difference between placebo and tiotropium in SGRQ improvement from baseline to 9 months was −6.00 points (p = 0.0003) ([Table 2](#t2-copd-3-301){ref-type="table"}).

Exacerbations
-------------

Patients treated with tiotropium experienced significantly fewer exacerbations per year (1.05 vs 1.83, 43% reduction; p = 0.03) and exacerbation days per year (10.5 vs 20.6, 49% reduction; p = 0.02) than those treated with placebo ([Table 3](#t3-copd-3-301){ref-type="table"}). A nonstatistically significant lower percentage of patients experienced 1 or more exacerbations during the 9-month study in the tiotropium group than in the placebo group (38.0% vs 45.1%; p = 0.10). In addition, tiotropium significantly delayed the time to first exacerbation compared with placebo; mean time to first exacerbation was 201 days in the tiotropium group vs 181 days in the placebo group (p = 0.0081).

Adverse events
--------------

The proportion of patients experiencing an adverse event was similar in the tiotropium and placebo group ([Table 4](#t4-copd-3-301){ref-type="table"}). The incidence of dry mouth was very low and similar in both groups (tiotropium, 1.1%; placebo, 0.7%). The proportion of patients with drug-related or serious adverse events or those withdrawing from the study due to adverse events or death were not significantly different ([Table 4](#t4-copd-3-301){ref-type="table"}). The number of deaths occurring during the study (3 in the tiotropium group and 6 in the placebo group) was not unexpected, given the age, severity of COPD, and prevalence of other serious comorbid conditions in the study population. There were 3 deaths in the tiotropium group (stroke (1), COPD (2)) and 6 deaths in the placebo group (COPD (1), pneumonia (1), suicide (2), respiratory failure (1) and aortic aneurysm (1)).

Discussion
==========

A fundamental aim of COPD management is to improve HRQoL. This 9-month study found that significantly more patients who received maintenance treatment with tiotropium 18 μg daily had a reduction of at least 4 units in the SGRQ total score in their HRQoL compared with those who received placebo. The clinical significance of the modification of −4 units is a matter of considerable discussion in the literature, including that authored by Dr Jones himself. However, the value of −4 units will be maintained to facilitate the discussion of the results obtained in this study.

These findings are consistent with previous studies that have shown significant improvements in SGRQ component and total scores with tiotropium ([@b9-copd-3-301]; [@b4-copd-3-301]; [@b29-copd-3-301]; [@b3-copd-3-301]; [@b28-copd-3-301]). The percentage of patients in the placebo group who had a reduction of at least 4 units in the SGRQ total score in this trial was somewhat higher (48%) compared with previous studies (30%--39%) ([@b4-copd-3-301]; [@b3-copd-3-301]; [@b28-copd-3-301]), although the proportions are similar to those reported by Donohue et al (tiotropium: 51%; placebo: 42%) ([@b9-copd-3-301]). While more placebo-treated patients withdrew from the study than those receiving tiotropium, this does not entirely explain the high placebo response as missing scores were imputed. The present study was performed over a 2-year period, with about 50% of patients identified and recruited in the first year; however, there was no change in COPD management during the 2 years. Therefore, there is no clear explanation for the higher-than-expected proportion of placebo-treated patients with HRQoL improvements. These levels for placebo responders are consistent with data from 4 internal studies of tiotropium, where the rate of placebo response was 29%--42% (data on file, Boehringer Ingelheim).

Nevertheless, the higher-than-expected percentage of responders in the placebo group is possibly explained by the focus of both patients and physicians on monitoring HRQoL as the primary endpoint of the trial. Furthermore, both may be supposed to have had higher expectations of the effect of tiotropium as the study was conducted at a time when tiotropium was already available in other European countries, but not in France: this assumption, nevertheless, remains hypothetical.

The mean SGRQ total score was significantly lower in the tiotropium group compared with the placebo group at baseline; however, all results presented are baseline adjusted.

Two previous 1-year studies have assessed the effects of tiotropium on HRQoL compared with placebo or ipratropium ([@b4-copd-3-301]; [@b29-copd-3-301]). In both these trials, improvement in SGRQ total scores reached a plateau after 3 to 6 months of treatment. Based on these data, 9 months was chosen as an appropriate timeframe for this study. However, future studies should address whether the observed improvements in HRQoL with tiotropium treatment are sustained over the longer term ([@b7-copd-3-301]). Furthermore, future studies should compare the effects of tiotropium vs short-acting anticholinergics or long-acting β~2~-agonists on HRQoL as a primary outcome.

We have conducted a number of subanalyses in this trial and tiotropium has consistently been shown to improve patients' HRQoL. As expected, the mean baseline SGRQ total score was significantly higher in patients with more severe disease (FEV~1~ ≤ 50% predicted) than in those with milder disease (FEV~1~ \> 50% predicted). In the subgroup analyses, tiotropium significantly improved SGRQ total score vs placebo in patients with more severe COPD (FEV~1~ ≤ 50% predicted). In the patients with milder COPD and an FEV~1~ \> 50% predicted, this difference did not reach statistical significance, despite the consistent efficacy of tiotropium. This finding is due to an unexpectedly high response in the placebo group in this subanalysis. Why this high response occurred cannot be explained from the data, due to the small subgroups analyzed here and the resulting lack of power, the possibility of a chance finding cannot be excluded. Another potential explanation could be that the differences in the drop-out rates between tiotropium and placebo might have contributed to this finding, but this remains speculative.

Compared with placebo, tiotropium also provided significantly greater improvements in SGRQ total score in patients not receiving ICS during the trial. In the subgroup of patients receiving ICS, there was a trend towards a significant improvement vs placebo and a statistically significant change vs baseline.

HRQoL has been recognized as a key outcome measure in COPD as it has been associated with lung function decline, exercise performance, and healthcare utilization ([@b8-copd-3-301]). Although the SGRQ has been proved unequivocally to be a useful tool to measure HRQoL in clinical trials, this large 76-item questionnaire is difficult to use for assessing individual patients in daily medical practice. Another recently developed instrument, the self-administered chronic respiratory questionnaire (CRQ), may be useful in clinical practice but had not been validated in French at the time of the study ([@b23-copd-3-301]). For this reason, the shorter 8-item VSRQ (French language version) has been developed and included in the present study. The VSRQ has the advantages of being both easy to use and unidimensional. However, further studies are needed to confirm its clinical responsiveness in individual patients.

In agreement with observations from previous large-scale clinical studies ([@b4-copd-3-301]; [@b29-copd-3-301]; [@b3-copd-3-301]; [@b5-copd-3-301]), tiotropium significantly improved spirometric parameters vs placebo. The physiologic hallmark of COPD is expiratory flow limitation ([@b21-copd-3-301], [@b20-copd-3-301]). In this study, treatment with tiotropium led to significant improvements in FEV~1~, FIV~1~, FVC, IC, and SVC compared with placebo. We hypothesize that the observed improvement in airflow and reduction in hyperinflation (measured by FVC, IC, and SVC) with tiotropium plays a major role in dyspnea relief, which allows patients to increase their day-to-day activity, thereby improving their HRQoL. Increasing evidence suggests that FEV~1~ is only weakly correlated with patient-centered outcomes, with consistently low correlation between lung function and SGRQ total scores ([@b21-copd-3-301], [@b20-copd-3-301]). In agreement with these findings, we did not find a relevant correlation between improvements in FEV~1~ and SGRQ total score at study end. In addition, this was the first study to investigate the impact of tiotropium on FIV~1~. Improvements in FIV~1~ after salbutamol inhalation have been shown to be closely correlated with dyspnea relief at rest ([@b26-copd-3-301]). Tiotropium significantly improved this lung function parameter to a similar extent as FEV~1~, FVC, IC, and SVC.

Tiotropium also significantly reduced the frequency of exacerbations and the number of exacerbation days over the 9-month treatment period. Since exacerbations have been shown to adversely affect patients' health status ([@b16-copd-3-301]; [@b6-copd-3-301]), a reduction in their frequency, the number of exacerbation days, or the time to first exacerbation, for example, would be highly likely to be associated with an improvement in patients' HRQoL.

In summary, compared with placebo, maintenance treatment with tiotropium 18 μg daily for 9 months provides statistically and clinically significant improvements in HRQoL in patients with COPD, assessed using the SGRQ. These results cannot be extrapolated to patients who require daytime oxygen therapy or have a significant disease other than COPD. In addition, tiotropium significantly improved spirometric parameters and reduced the incidence of exacerbations and the number of exacerbation days in patients with COPD.
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![Adjusted mean (SE) change from baseline in SGRQ scores in patients taking tiotropium or placebo: **a**) change in total score during the 9-month study; and **b**) change in domain scores at study end (means adjusted for baseline SGRQ scores).](copd-3-301f3){#f3-copd-3-301}

![Adjusted mean (SE) change from baseline in spirometric parameters at study end (means adjusted for baseline values).](copd-3-301f4){#f4-copd-3-301}

###### 

Patient demographics and characteristics at pretreatment baseline

                                                                   Tiotropium      Placebo
  ---------------------------------------------------------------- --------------- ---------------
  Patients, n                                                      266             288
  Sex, M/F                                                         231/35          246/42
  Age, years                                                       64.9 ± 9.7      63.5 ± 10.1
  Body mass index, kg/m^2^                                         26.0 ± 4.8      25.8 ± 4.7
  Duration of COPD, years                                          7.9 ± 7.6       8.0 ± 7.9
  Smoking history, pack-years                                      44.4 ± 21.3     43.0 ± 22.5
  Current smokers, n (%)                                           63 (23.7)       87 (30.2)
  HRQoL[a](#tfn2-copd-3-301){ref-type="table-fn"}                                  
   SGRQ total score                                                45.8 ± 17.7     48.9 ± 18.4
   VSRQ total score[b](#tfn3-copd-3-301){ref-type="table-fn"}      47.3 ± 16.0     43.3 ± 16.9
  Pulmonary function                                                               
   FEV~1~, L                                                       1.38 ± 0.44     1.35 ± 0.46
   FEV~1~, % predicted                                             47.49 ± 13.27   46.19 ± 12.40
   FVC, L                                                          2.50 ± 0.68     2.49 ± 0.75
   FEV~1~/FVC, %                                                   55.30 ± 11.32   54.62 ± 11.27
   IC, L                                                           2.14 ± 0.69     2.09 ± 0.69
   SVC, L                                                          2.78 ± 0.74     2.70 ± 0.78
   FIV~1~, L[c](#tfn4-copd-3-301){ref-type="table-fn"}             2.02 ± 0.64     2.04 ± 0.71
  Reversibility, n (%)[d](#tfn5-copd-3-301){ref-type="table-fn"}   108 (40.6)      116 (40.3)

Data are presented as mean ± SD unless otherwise stated.

*Lower* SGRQ but *higher* VSRQ scores indicate an improvement.

VSRQ total score was complete in 415 patients (tiotropium: n = 233; placebo: n = 237).

FIV~1~ was assessed only at selected sites (80.5% of patients in the full analysis population, tiotropium: n = 233; placebo: n = 237).

Reversibility to a short-acting β~2~-agonist.

###### 

Mean change from baseline in SGRQ total score at study end according to COPD severity, reversibility at baseline, and ICS use during the trial

                                                            Tiotropium   Placebo                                                           
  --------------------------------------------------------- ------------ -------------- ----- -------------- -------------- -------------- --------
  COPD severity                                                                                                                            
   FEV~1~ \> 50% predicted                                  105          −8.85 ± 1.37   93    −7.38 ± 1.44   −1.47 (1.99)   −5.37, 2.44    0.4604
   FEV~1~ ≤ 50% predicted                                   140          −8.18 ± 1.18   150   −2.18 ± 1.14   −6.00 (1.64)   −9.21, −2.78   0.0003
  ICS use                                                                                                                                  
   Not receiving ICS                                        154          −9.22 ± 1.13   156   −4.81 ± 1.13   −4.41 (1.60)   −7.55, −1.27   0.0061
   Receiving ICS                                            93           −7.32 ± 1.46   89    −3.45 ± 1.49   −3.87 (2.09)   −7.97, 0.24    0.0648
  Reversibility[a](#tfn8-copd-3-301){ref-type="table-fn"}                                                                                  
   Yes                                                      101          −8.78 ± 1.40   100   −4.20 ± 1.41   −4.58 (1.99)   −8.49, −0.68   0.0215
   No                                                       143          −8.25 ± 1.18   144   −4.48 ± 1.17   −3.76 (1.66)   −7.02, −0.50   0.0239
  Exacerbation                                                                                                                             
   Yes                                                      95           −7.21 ± 1.44   119   −2.15 ± 1.28   −5.06 ± 1.92   −8.84, −1.28   0.0089
   No                                                       152          −9.33 ± 1.14   126   −6.35 ± 1.25   −2.98 ± 1.69   −6.30, 0.35    0.0791

Lower SGRQ total scores indicate an improvement.

Means are adjusted for baseline SGRQ total scores using the following analysis of covariance model: Change from baseline of SGRQ total score = treatment + subgroup + subgroup-by-treatment interaction + baseline.

Reversibility to a short-acting β~2~-agonist.

Full analysis set was analyzed. Number of patients with available data may differ in each subgroup.

The interaction of treatment and subgroup was not significant with p values of 0.0787, 0.8364, 0.7510, and 0.4177, respectively for severity of the illness, ICS use, reversibility, and exacerbation on treatment.

###### 

Percentage of patients with ≥1 exacerbation, and mean number of exacerbations and exacerbation days per patient per year

                                                   Tiotropium   Placebo   Difference   95% CI         p value
  ------------------------------------------------ ------------ --------- ------------ -------------- ---------
  Patients with ≥1 exacerbation, %                 38.0         45.1      −7.2         −15.4, 1.00    0.1013
  Number of exacerbations/patient/year, n          1.05         1.83      −0.77        −1.37, −0.20   0.0287
  Number of exacerbation days/patient/year, days   10.5         20.6      −10.1        −16.5, −3.64   0.0213

###### 

Adverse event profile

                                                                        Tiotropium   Placebo
  --------------------------------------------------------------------- ------------ ------------
  Patients, n                                                           266          288
  At least 1 adverse event                                              162 (60.9)   193 (67.0)
  Drug-related adverse events                                           12 (4.5)     8 (2.8)
  Deaths                                                                3 (1.1)      6 (2.1)
  Serious adverse events                                                42 (15.8)    38 (13.2)
  Adverse events leading to discontinuation                             5 (1.9)      16 (5.6)
  Selected adverse events:[a](#tfn12-copd-3-301){ref-type="table-fn"}                
   COPD exacerbations                                                   65 (24.4)    80 (27.8)
   Bronchitis                                                           27 (10.2)    33 (11.5)
   Superinfection of the lung                                           18 (6.8)     20 (6.9)
   Rhinitis                                                             9 (3.4)      7 (2.4)

Data expressed as n (%) unless otherwise indicated.

Occurring in 3% or more of patients by treatment.

[^1]: See [Appendix](#app1-copd-3-301){ref-type="app"}: participating investigators
